Jurgi Camblong Sells 12,232 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04. Following the transaction, the chief executive officer directly owned 3,711,968 shares in the company, valued at $17,520,488.96. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $4.96 on Wednesday. The company’s 50 day simple moving average is $4.74 and its 200-day simple moving average is $4.72. The company has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analysts’ expectations of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, equities research analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of large investors have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its position in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $6,708,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $2,009,000. Finally, 1492 Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $973,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Aggregate insider activity: company executives and other insiders sold a combined ~43,400 shares across transactions on April 10 and April 13. Sales were executed under pre-arranged Rule 10b5-1 plans and were reported in SEC Form 4 filings. SEC Form 4
• Neutral Sentiment: CEO Jurgi Camblong sold 12,232 shares on April 10 and 4,399 shares on April 13 (total ~16,631 shares). Trades were made under a 10b5-1 plan to cover tax withholding tied to equity vesting; his remaining direct stake remains large (>3.7M shares). SEC Form 4
• Neutral Sentiment: President Ross Muken sold 3,687 shares on April 10 and 4,442 shares on April 13 (~8,129 shares). Transactions were under a 10b5-1 plan and described as tax-related for vested awards. SEC Form 4
• Neutral Sentiment: Other insiders (Philippe Menu and Zhenyu Xu) each made paired sales on April 10 and April 13 totaling ~8,125 and ~8,120 shares respectively; Well Daan Van sold 2,400 shares on April 10. All trades were 10b5-1, tax-withholding sales. SEC Form 4 (Menu) SEC Form 4 (Xu) SEC Form 4 (Van)

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.